# Tucatinib Clearance, Genetics, and Enzyme Inducers

Tucatinib is cleared mainly through **CYP2C8** and **CYP3A4**. That means drug exposure may vary because of genetics, co-medications, and supplements that induce or inhibit these enzymes.

### Why this matters

If tucatinib is cleared too quickly, drug exposure may fall.

If tucatinib is cleared too slowly, side effects may become more likely.

In practice, the most important questions are usually:

* whether another drug or supplement is changing enzyme activity
* whether inherited variation may be affecting clearance
* whether reduced exposure could be contributing to loss of efficacy

### Genetic variation that may matter

Potentially relevant genes include:

* **CYP3A4**
* **CYP2C8**
* **ABCB1**

Examples often discussed include:

* **CYP3A4\*22** — associated with lower CYP3A4 activity in some settings
* **CYP3A4\*1G** — sometimes associated with higher activity
* **CYP2C8 variants** such as \*2 and \*3 — may alter substrate handling
* **ABCB1 polymorphisms** — may affect drug transport and intracellular exposure

These findings are helpful context, but they do not yet translate into routine personalised tucatinib dosing for most patients.

### Enzyme inducers that may increase tucatinib clearance

Known or plausible inducers include:

* **St John's wort**
* **rifampicin**
* **carbamazepine**
* **phenytoin**
* some **antiretrovirals,** such as efavirenz or nevirapine
* lower dose (not high-dose) **Ivermectin**

These may reduce tucatinib exposure by increasing CYP3A4 or CYP2C8 activity.

### Natural-compound relevance

Natural compounds are usually discussed more often as **inhibitors** than as strong inducers.

One major exception is **St John's wort**, a classic inducer that should be treated as a high-priority interaction concern.

Evidence for mild induction from other supplements, including some omega-3 discussions, is much weaker and less clinically established.

### Questions to discuss with the care team

* whether pharmacogenetic testing is available and useful
* whether any current medicines or supplements may be inducing CYP3A4 or CYP2C8
* whether the unexpected loss of efficacy could relate to altered exposure
* whether liver function, toxicity pattern, or co-medications suggest a clearance issue

### Related pages

* [HER2CLIMB Guide](/myhealingcommunity-docs/breast-cancer/her2-positive/her2climb/her2climb-guide.md)
* [Natural Compounds and CYP3A4 — HER2CLIMB Considerations](/myhealingcommunity-docs/breast-cancer/her2-positive/her2climb/natural-compounds-and-cyp3a4-her2climb-considerations.md)
* [HER2CLIMB Resistance Mechanisms](/myhealingcommunity-docs/breast-cancer/her2-positive/her2climb/her2climb-resistance-mechanisms.md)

### References

Impact of variation in CYP3A and CYP2C8 on tucatinib metabolic clearance\
<https://www.sciencedirect.com/science/article/abs/pii/S0090955625090701>

Kinetic and mechanistic investigation toward the characterization of tucatinib metabolism\
<https://pubmed.ncbi.nlm.nih.gov/40812076/>

CYP3A4\*22 Genotype-Guided Dosing of Kinase Inhibitors in Cancer\
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10386914/>

The Pharmacokinetics and Safety of Tucatinib in Volunteers\
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9734226/>

FDA multidisciplinary review for tucatinib\
<https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213411Orig1s000MultidisciplineR.pdf>

<p align="center"><strong>Would you like to ask Abbey about the information shared on this page? Would you like to contribute your experience, research or ideas to this page? Perhaps you want to point out something that needs changing?</strong></p>

<p align="center"><a href="https://docs.google.com/forms/d/e/1FAIpQLSeyUv3ff9uIwelzyKtOYE2J_HOzhaY5gEV4Xm2Xyr8KX67zxA/viewform?usp=header" class="button primary" data-icon="comment">Feedback Form</a></p>

{% hint style="warning" %}
This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use.
{% endhint %}

{% hint style="info" %}
© 2026 Abbey Mitchell. All rights reserved. Please share by URL rather than copying page text.
{% endhint %}


---

# Agent Instructions: Querying This Documentation

If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question.

Perform an HTTP GET request on the current page URL with the `ask` query parameter:

```
GET https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/breast-cancer/her2-positive/her2climb/tucatinib-clearance-genetics-and-enzyme-inducers.md?ask=<question>
```

The question should be specific, self-contained, and written in natural language.
The response will contain a direct answer to the question and relevant excerpts and sources from the documentation.

Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.